Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 304, Issue 9, 2013, Pages

  Saleh, Mohammad I ^a   Nalbant, Demet ^a   Widness, John A ^b   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Erythropoiesis; Gestational age; Pharmacodynamics; Preterm infants

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN;

ANEMIA; ARTICLE; BLOOD SAMPLING; BLOOD VOLUME; CLINICAL ARTICLE; DRUG EFFICACY; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FEMALE; GESTATIONAL AGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFANT; MALE; POPULATION RESEARCH; PREMATURITY; PRIORITY JOURNAL; SIMULATION;

ERYTHROPOIESIS; GESTATIONAL AGE; PHARMACODYNAMICS; PRETERM INFANTS;

ADULT; ALGORITHMS; ANEMIA; BLOOD VOLUME; DATA INTERPRETATION, STATISTICAL; ERYTHROCYTE AGING; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; GESTATIONAL AGE; HEMOGLOBINS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; MODELS, STATISTICAL; PHLEBOTOMY; PLASMA SUBSTITUTES; POPULATION; PREGNANCY; RECOMBINANT PROTEINS;

EID: 84878650358     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00173.2012     Document Type: Article

References (53)

1. Al-Huniti NH, Widness JA, Schmidt RL, Veng-Pedersen P. Pharmacokinetic/ pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. J Pharmacol Exp Ther 310: 202-208, 2004.
2. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24: 25-36, 2009.
3. Arbuckle TE, Wilkins R, Sherman GJ. Birth weight percentiles by gestational age in Canada. Obstet Gynecol 81: 39-48, 1993.
4. Arif B, Ferhan K. Recombinant human erythropoietin therapy in lowbirthweight preterm infants: a prospective controlled study. Pediatr Int 47: 67-71, 2005.
5. Avent M, Cory BJ, Galpin J, Ballot DE, Cooper PA, Sherman G, Davies VA. A comparison of high versus low dose recombinant human erythropoietin versus blood transfusion in the management of anaemia of prematurity in a developing country. J Trop Pediatr 48: 227-233, 2002.
6. Bazzoli C, Retout S, Mentre F. Fisher information matrix for nonlinear mixed effects multiple response models: evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model. Stat Med 28: 1940-1956, 2009.
7. Berlin NI, Waldmann TA, Weissman SM. Life span of red blood cell. Physiol Rev 39: 577-616, 1959.
8. Brugnara C, Platt OS. The neonatal erythrocyte and its disorders. In: Nathan and Oski's Hematology of Infancy and Childhood, edited by Nathan DG, Orkin SH, Ginsburg D, Look AT. Philadelphia, PA: Saunders, 2003, p. 19-55.
9. Carbonell-Estrany X, Figueras-Aloy J, Alvarez E. Erythropoietin and prematurity-where do we stand? J Perinat Med 33: 277-286, 2005.
10. Costa E, Belo L, Quintanilha A, Santos-Silva A. Resistance to recombinant human erythropoietin therapy in haemodialysis patients: focus on inflammatory cytokines, leukocyte activation, iron status and erythrocyte damage. J Nephrol Ren Transplant 2: 66-83, 2009.
11. Costa E, Lima M, Alves JM, Rocha S, Rocha-Pereira P, Castro E, Miranda V, do SF, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol 28: 268-275, 2008.
12. Costa E, Pereira BJ, Rocha-Pereira P, Rocha S, Reis F, Castro E, Teixeira F, Miranda V, do Sameiro Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol 28: 677-683, 2008.
13. Costa E, Rocha S, Rocha-Pereira P, Nascimento H, Castro E, Miranda V, Faria M, Loureiro A, Quintanilha A, Belo L, Santos-Silva A. Neutrophil activation and resistance to recombinant human erythropoietin therapy in hemodialysis patients. Am J Nephrol 28: 935-940, 2008.
14. Dallman PR. Anemia of prematurity. Annu Rev Med 32: 143-160, 1981.
15. Dame C, Fahnenstich H, Freitag P, Hofmann D, Abdul-Nour T, Bartmann P, Fandrey J. Erythropoietin mRNA expression in human fetal and neonatal tissue. Blood 92: 3218-3225, 1998.
16. De Alarcón PA, Johnson MC, Werner EJ. Erythropoiesis, red cells, and the approach to anemia. In: Neonatal Hematology, edited by De Alaŕcon PA, Werner EJ. Cambridge, UK: Cambridge University Press, 2005, p. 40-57.
17. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest 35, Suppl 3: 13-19, 2005.
18. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78, 1987.
19. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 228: 1-14, 2003.
20. Fisher JW. Landmark advances in the development of erythropoietin. Exp Biol Med (Maywood) 235: 1398-1411, 2010.
21. Freise KJ, Widness JA, Veng-Pedersen P. Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants. J Pharmacol Exp Ther 332: 229-237, 2010.
22. Garby L, Sjoelin S, Vuille JC. Studies on erythro-kinetics in infancy. III. Disappearance from plasma and red-cell uptake of radio-active iron injected intravenously. Acta Paediatr 52: 537-553, 1963.
23. Gonzalez-Baron M, Ordonez A, Franquesa R, Constenla M, Montalar J, Gili F, Camps C, Sancho JF, Perez-Cachot P. Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy. Cancer 95: 2408-2413, 2002.
24. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72, 1999.
25. Halperin DS, Wacker P, Lacourt G, Felix M, Babel JF, Aapro M, Wyss M. Effects of recombinant human erythropoietin in infants with the anemia of prematurity: a pilot study. J Pediatr 116: 779-786, 1990.
26. Hess JR, Hill HR, Oliver CK, Lippert LE, Rugg N, Joines AD, Gormas JF, Pratt PG, Silverstein EB, Greenwalt TJ. Twelve-week RBC storage. Transfusion 43: 867-872, 2003.
27. Jonsson EN, Wade JR, Karlsson MO. Nonlinearity detection: advantages of nonlinear mixed-effects modeling. AAPS PharmSci 2: E32, 2000.
28. Krzyzanski W, Woo S, Jusko WJ. Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J Pharmacokinet Pharmacodyn 33: 125-166, 2006.
29. Lichtman MA, Williams WJ. Williams Hematology. New York: McGraw-Hill Medical, 2006.
30. Luten M, Roerdinkholder-Stoelwinder B, Schaap NP, de Grip WJ, Bos HJ, Bosman GJ. Survival of red blood cells after transfusion: a comparison between red cells concentrates of different storage periods. Transfusion 48: 1478-1485, 2008.
31. Maier RF, Obladen M, Scigalla P, Linderkamp O, Duc G, Hieronimi G, Halliday HL, Versmold HT, Moriette G, Jorch G, Verellen G, Semmekrot BA, Grauel EL, Holland BM, Wardrop C. The effect of epoetin beta (recombinant human erythropoietin) on the need for transfusion in very-low-birth-weight infants. European Multicentre Erythropoietin Study Group. N Engl J Med 330: 1173-1178, 1994.
32. Mainie P. Is there a role for erythropoietin in neonatal medicine? Early Hum Dev 84: 525-532, 2008.
33. McQueen R. Hematology in selected populations. In: Hematology: Clinical Principles and Applications, edited by Rodak BF, Fritsma GA, Doig K. St. Louis, MO: Saunders, 2007, p. 526-540.
34. Mehta R. Anemias: RBC morphology and approach to diagnosis. In: Hematology: Clinical Principles and Applications edited by Rodak BF, Fritsma GA, Doig K. St. Louis, MO: Saunders, 2007, p. 219-231.
35. Mock DM, Matthews NI, Zhu S, Strauss RG, Schmidt RL, Nalbant D, Cress GA, Widness JA. Red blood cell (RBC) survival determined in humans using RBCs labeled at multiple biotin densities. Transfusion 51: 1047-1057, 2011.
36. Moroff G, Holme S, AuBuchon JP, Heaton WA, Sweeney JD, Friedman LI. Viability and in vitro properties of AS-1 red cells after gamma irradiation. Transfusion 39: 128-134, 1999.
37. Necas E, Neuwirt J. Feedback regulation by red cell mass of the sensitivity of the erythropoietin-producing organ to hypoxia. Blood 36: 754-763, 1970.
38. Ohls RK, Ehrenkranz RA, Wright LL, Lemons JA, Korones SB, Stoll BJ, Stark AR, Shankaran S, Donovan EF, Close NC, Das A. Effects of early erythropoietin therapy on the transfusion requirements of preterm infants below 1250 grams birth weight: a multicenter, randomized, controlled trial. Pediatrics 108: 934-942, 2001.
39. Ohls RK, Osborne KA, Christensen RD. Efficacy and cost analysis of treating very low birth weight infants with erythropoietin during their first two weeks of life: a randomized, placebo-controlled trial. J Pediatr 126: 421-426, 1995.
40. Palis J, Segel GB. Developmental biology of erythropoiesis. Blood Rev 12: 106-114, 1998.
41. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 65: 2371-2379, 2004.
42. Ramakrishnan R, Cheung WK, Wacholtz MC, Minton N, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J Clin Pharmacol 44: 991-1002, 2004.
43. Rawnaq T, Schwarzenbach H, Schurr PG, Freise K, Brandl S, Izbicki JR, Kaifi JT. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res 169: 31-35, 2011.
44. Roback J, Combs M, Grossman B, Hillyer C (Editors). Technical Manual (16th ed.). Bethesda, MD: American Association of Blood Banks, 2008.
45. Saleh MI, Widness JA, Veng-Pedersen P. Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep. Biopharm Drug Dispos 32: 131-139, 2011.
46. Shannon KM, Keith JF 3rd, Mentzer WC, Ehrenkranz RA, Brown MS, Widness JA, Gleason CA, Bifano EM, Millard DD, Davis CB, Stevenson DK, Alverson DC, Simmons CF, Brim M, Abels RI, Phibbs RH. Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. Pediatrics 95: 1-8, 1995.
47. Strauss RG, Mock DM, Widness JA, Johnson K, Cress G, Schmidt RL. Posttransfusion 24-hour recovery and subsequent survival of allogeneic red blood cells in the bloodstream of newborn infants. Transfusion 44: 871-876, 2004.
48. Suzuki N, Obara N, Pan X, Watanabe M, Jishage K, Minegishi N, Yamamoto M. Specific contribution of the erythropoietin gene 3= enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol 31: 3896-3905, 2011.
49. Usher R, Lind J. Blood volume of the newborn premature infant. Acta Paediatr Scand 54: 419-431, 1965.
50. Valieva OA, Strandjord TP, Mayock DE, Juul SE. Effects of transfusions in extremely low birth weight infants: a retrospective study. J Pediatr 155: 331.e1-337.e1, 2009.
51. Wahlby U, Jonsson EN, Karlsson MO. Assessment of actual significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 28: 231-252, 2001.
52. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci 4: E27, 2002.
53. Zanjani ED, Poster J, Burlington H, Mann LI, Wasserman LR. Liver as the primary site of erythropoietin formation in the fetus. J Lab Clin Med 89: 640-644, 1977.